



# Drugs of Choice (DOC) List

More details and updated versions may be downloaded at [www.ncdoclist.com](http://www.ncdoclist.com)  
\*includes combination product of same generic drug

ANALGESICS	metronidazole	atenolol*	phenytoin
Short Acting Narcotics	Acyclovir	carvedilol*	gabapentin
hydrocodone/APAP	BEHAVIORAL HEALTH	metoprolol tartrate*	lamotrigine
codeine/APAP	ADHD	Calcium Channel Blockers	levetiracetam
oxycodone IR*	amphetamine salt combo	amlodipine*	topiramate
morphine sulfate IR	dextroamphetamine	nifedipine/nifedipine ER	Antiparkinson/Restless Leg
NSAIDS	dexmethylphenidate	diltiazem/diltiazem ER	benztropine
diclofenac	methylphenidate	verapamil/verapamil ER*	carbidopa/levodopa
ibuprofen	Antipsychotics	Diuretics	pramipexole
meloxicam	haloperidol	hydrochlorothiazide	ropinirole
naproxen	clozapine	furosemide	Sedative Hypnotics
Other Analgesic	risperidone	spironolactone	temazepam
tramadol	Quetiapine	Coronary Vasodilators	zolpidem
ORAL ANTI-INFECTIVES	Antidepressants	isosorbide dinitrate	Skeletal Muscle Relaxants
Antifungals	amitriptyline	isosorbide mononitrate	baclofen
fluconazole	bupropion	nitroglycerin SL tabs	cyclobenzaprine
nystatin	mirtazapine	Antiarrhythmics	tizanidine
terbinafine	trazodone	amiodarone	Smoking Cessation
Cephalosporins and Related	citalopram	digoxin	bupropion SR
amoxicillin/clavulanate	fluoxetine	Antiplatelet	nicotine patch
cephalexin	sertraline	clopidogrel	Migraine
cefdinir	paroxetine/paroxetine CR	dipyridamole	sumatriptan
Macrolides	venlafaxine/venlafaxine ER	ticlopidine	ENDOCRINE
Azithromycin	Anxiolytics	Fibrates	Thyroid Replacement
Quinolones	alprazolam	gemfibrozil	levothyroxine sodium
ciprofloxacin	clonazepam	Statins	Levoxyl
levofloxacin	lorazepam	lovastatin	liothyronine
Tetracyclines	CARDIOVASCULAR	pravastatin	Hormone Replacement
doxycycline hydiate	ACE Inhibitors	simvastatin	estradiol
minocycline IR	benazepril*	CENTRAL NERVOUS SYSTEM	estradiol patch
tetracycline	enalapril*	Anticonvulsants	estradiol/norethindrone
Other	lisinopril*	carbamazepine	Oral Contraceptives
clindamycin	Beta Blockers	oxcarbazepine	monophasic: Sprintec
SMX/TMP		divalproex	biphasic: Kariva

triphasic: Tri-Sprintec	ranitidine	Glaucoma	Antifungals
high-dose: Ogestrel	<b>Proton Pump Inhibitors</b>	brimonidine	clotrimazole
extended cycle: Jolessa	omeprazole	timolol*	ketoconazole
noncyclic: Amethyst	pantoprazole	dorzolamide*	nystatin
progestin only: Camila	<b>GENITOURINARY</b>	<b>Prostaglandin Agonists</b>	<b>Anti-Infectives (Acne)</b>
<b>Oral Hypoglycemics</b>	<b>BPH</b>	latanoprost	benzoyl peroxide
glimepiride	doxazosin	<b>OTICS</b>	clindamycin phosphate
glipizide/glipizide XL	terazosin	<b>Antibiotics</b>	erythromycin
glyburide	finasteride	neomycin/polymyxin B/TMP	<b>Anti-Infectives (Non-Acne)</b>
acarbose	<b>Urinary Antispasmodic</b>	<b>RESPIRATORY</b>	mupirocin
metformin	oxybutynin	<b>Beta Agonist Nebs</b>	<b>Anti-Inflammatory</b>
nateglinide	<b>HEMATOLOGIC</b>	albuterol sulfate	<i>Low potency:</i> hydrocortisone
<b>Oral Glucocorticoids</b>	<b>Anticoagulants</b>	<b>COPD</b>	<i>Med potency:</i> mometasone
methylprednisolone	warfarin	ipratropium bromide	<i>High potency:</i> triamcinolone
prednisone	<b>OPHTHALMICS</b>	<b>Non-Sedating Antihistamines</b>	<i>Very High potency:</i> clobetasol
<b>GASTROINTESTINAL</b>	<b>Anti-Infectives</b>	cetirizine	<b>MISCELLANEOUS</b>
<b>Antiemetics</b>	ciprofloxacin	loratadine	<b>Gout</b>
meclizine	erythromycin	<b>Intranasal Rhinitis</b>	allopurinol
metoclopramide	polymyxin B/TMP	fluticasone	<b>Osteoporosis</b>
promethazine	tobramycin	flunisolide	alendronate
<b>H-2 Receptor Antagonists</b>	<b>Anti-Inflammatory</b>	<b>TOPICALS</b>	
famotidine	prednisolone		

**Round 1:** Determine *classes of medications* with any *individual drugs* in the top 100 by volume lists (Drug Topics, Pharmacy Times).

**Round 2:** Consider drugs within the class for further review if all of:

1. Preferred by NC Medicaid/Health Choice without a prior authorization (PA) or clinical criteria
2. Categorized as Tier 1 by Blue Cross Blue Shield (BCBS) NC
3. Categorized as Tier 1 by NC State Health Plan

**Round 3:** Using individual drugs remaining within a class after Round 2, perform a NC Medicaid market share analysis.\*

**Round 4:** Conduct a cost evaluation on all remaining Round 3 agents using agents within each respective class as the main cost comparators.\*\*

\*Market shares based on fill volume and cumulative percentage with NC Medicaid. Drugs that comprise 90% cumulative market share, not to exceed the top 4 drugs within the class, continued to Round 4 for cost analysis.

\*\*The cost of the medication for an uninsured patient was collected from three pharmacies for each unique drug, strength and form, with each pharmacy-drug combination being selected at random. Final determination of DOC list inclusion was based on cost relative to drugs within same class, but not to exceed a cost threshold set for all classes.

